Visipaque
Sponsors
Rigshospitalet, Guerbet, Chinese PLA General Hospital, GE Healthcare
Conditions
Cardio-Renal SyndromeChronic Kidney DiseasesDiagnostic ImagingPancreatic cancer and gastroesophageal cancer (esophagusgastroesophageal junction (GEJ) and gastric cancer)
Phase 2
BEFAST STUDY: [68Ga]Ga-FAPI total body PET/CT for Better and Faster imaging in cancer
Protocol: [68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic cancer
WithdrawnCTIS2023-503632-41-00
Target: 60Updated: 2023-06-14
BEFAST STUDY: [68Ga]Ga-FAPI total body PET/CT for Better and Faster imaging in cancer
Protocol: [68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic cancer
RecruitingCTIS2023-503632-41-01
Start: 2024-01-30Target: 90Updated: 2025-12-10
Phase 4
A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications
CompletedNCT00347022
Start: 2006-05-31End: 2009-06-30Updated: 2013-04-09
A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
TerminatedNCT03119662
Start: 2018-02-08End: 2018-10-19Updated: 2019-12-17
Unknown Phase
Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy
CompletedNCT02405377
Start: 2014-02-28End: 2015-02-28Updated: 2015-04-01
Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN
NCT02718521
Start: 2016-03-31End: 2017-04-30Target: 400Updated: 2016-03-24